Abstract Purpose: Patients with pancreatic adenocarcinoma have a poor prognosis due to the extraordinary high invasive capacity of this tumor. Altered integrin and tetraspanin expression is suggested to be an important factor.We recently reported that after protein kinase C activation, colocalization of a6h4 with the tetraspanin CO-029 strongly supports migration of a rat pancreatic adenocarcinoma. The finding led us to explore whether and which integrin-tetraspanin complexes influence the motility of human pancreatic tumors. Experimental Design: Integrin and tetraspanin expression of pancreatic and colorectal adenocarcinoma was evaluated with emphasis on colocalization and the impact of integrin-tetraspanin associations on tumor cell motility. Results: The majority of pancreatic and colorectal tumors expressed the a2, a3, a6, h1, and h4 integrins and the tetraspanins CD9, CD63, CD81, CD151, and CO-029. Expression of a6h4 and CO-029 was restricted to tumor cells, whereas a1, a2, a3, a6, h1, and CD9, CD81, CD151 were also expressed by the surrounding stroma. CD63, CD81, and h1expression was observed at comparably high levels in healthy pancreatic tissue. a3h1frequently colocalized and coimmunoprecipitated with CD9, CD81, and CD151, whereas a6h4 colocalized and coimmunoprecipitated mostly with CD151and CO-029. Notably, protein kinase C activation strengthened only the colocalization of CD151and CO-029 with h4 and was accompanied by internalization of the integrintetraspanin complex, decreased laminin 5 adhesion, and increased cell migration. Conclusion: a6h4 is selectively up-regulated in pancreatic and colorectal cancer. The association of a6h4 with CD151and CO-029 correlates with increased tumor cell motility.
Pancreatic adenocarcinoma is a leading cause of cancer-related death and the frequency is increasing steadily (1) . Patients with pancreatic adenocarcinoma have a very poor prognosis, the 1-year survival rate being <20% and the 5-year survival rate being <1% in most clinical centers. This is partly due to the fact that >80% of patients have massive metastatic spread at the time of diagnosis (1, 2) . The early spread is proposed to proceed after settling of tumor cells in the peritoneal cavity and the penetration into blood vessels via so-called peritoneal pores, with formation of metastases preferentially in the liver (3) . The mechanisms underlying the extraordinarily high invasive capacity of pancreatic adenocarcinoma are not yet understood. It is suggested that altered expression of adhesion molecules, particularly of integrins, might be an important factor (4) .
Changes in expression of integrins, particularly, a3h1 and a6h4, are frequently related to the metastatic capacity of tumor cells (5, 6) . Reports on the integrin expression profile in pancreatic adenocarcinoma revealed partly contradictory results. It has been described that a2, a3, a5, a6, av, h1, and h4 are overexpressed in pancreatic adenocarcinoma lines, that do not express the a1, a4, or h2 integrins (7) . High a6 expression on tumor tissue and weak expression on the surrounding tissue together with low expression of a5 (8) , or high a6h4 expression together with high laminin 5 secretion may also indicate a poor prognosis (9) . In the nude mouse, high a6 and avh5 expression and low a2 expression was associated with metastasis (10) . However, other reports indicate that pancreatic adenocarcinoma tissues display weak a6 expression, but high a2, a3, a4, av, and h1 levels (11) . Other studies revealed tumor-related a2 and a6 up-regulation with a diffuse staining pattern (12) . High h4 expression (7) was confirmed by sophisticated molecular profiling, that took into account the strong stromal reaction of pancreatic adenocarcinoma as well as the features of chronic pancreatitis (13) .
Tetraspanins are also known to contribute to the metastatic process (14 -16) . Whereas CD63 expression does not seem to be of major impact (17) , high CD9 (18 -21) , and CD82 (19, 22, 23) expression has been associated with a favorable prognosis in gastrointestinal tumors. In contrast, high CD151 and CO-029 expression seem to promote metastasis formation (18, 24) .
Tetraspanins are known to form protein complexes, mostly composed of different tetraspanins and integrins (25, 26) , which influence cell motility (27 -29) . The strongest complexes are formed between CD151 and a3 (26, 28, 30) . CD151 also associates with a6h4, notably in hemidesmosomes (31) . CD9 mostly associates with a3h1 and may associate with a6h4 outside of hemidesmosomes (32, 33) . Whether integrins associate with CO-029 in human tissues has not been explored. The rat homologue of CO-029, D6.1A, associates with a3 and a6h1 (14) and, after protein kinase C (PKC) activation, with a6h4 (34).
We had noted in a rat pancreatic adenocarcinoma that coexpression of a6h4 and the D6.1A tetraspanin, but not overexpression of a6h4 by itself, contributes to the hematogeneous spread of tumor cells (34) . In view of the poor prognosis for patients with pancreatic adenocarcinoma, it became of interest to explore integrin-tetraspanin associations and their potential impact on cell motility in human pancreatic adenocarcinoma.
Materials and Methods
Tumors and tumor lines. Pancreatic adenocarcinoma (30) , normal pancreatic (5) , and chronic pancreatitis (10) tissues were collected during surgery and snap-frozen in liquid nitrogen. Histologic type and grading of the tumors are shown in the supplement (Table S1 ). Informed consent on tissue collection was obtained from each patient and tissue collection was approved by the University Ethics Review Board. Tissue culture lines were established from the pancreatic tumors P73, P106, and P122. These lines consisted of a mixture of tumor cells and stromal elements, the presence of the stroma being essential for tumor cell survival. The long-term pancreatic adenocarcinoma lines AsPC1, BxPC3, Capan1, Capan2, Colo357, MiaPaca1, Panc1, Panc89, Pt45P1, PancTu1, and 8.18 were maintained in RPMI 1640, supplemented with 10% FCS, nonessential amino acids, and 10 mmol/L sodium pyruvate. The long-term colorectal cancer lines Colo320, Colo320DM, HT29, Lovo, SW480, SW707, SW948, and WIDR were maintained in RPMI 1640 and supplemented with 10% FCS. Lines are described in the supplement (Table S2 ). All lines grew adherent and, when confluent, were detached with trypsin for subculture.
Antibodies and staining procedures. The following monoclonal antibodies have been used: anti-CD9, anti-CD18 (h2), anti-CD29 (h1), anti-CD49a (a1), anti-CD49b (a2), anti-CD49c (a3), antiCD49e (a5), anti-CD49f (a6), anti-CD53, anti-CD63, anti-CD81, anti-CD82, anti-CD104 (h4), anti-CD151, anti-CO-029 (see supplement, Table S3 for clone description). Where indicated ascitic fluid or hybridoma culture supernatants were purified by passage over protein G Sepharose and were labeled with biotin, FITC, or rhodamine. Dye-labeled secondary antibodies and streptavidin were obtained commercially (BD/PharMingen and Dianova, Hamburg, Germany). A1 A2  A3  A4 A5  A6  AL  B1  B2  B4 CD9 CD53 CD63 CD81 CD82 CD151 CO-029 Pancreatic cancer AsPC1 Flow cytometry followed routine procedures using 1 to 3 Â 10 5 tumor cells per sample. Trypsinized cells were allowed to recover for 2 hours at 37jC in RPMI 1640, 10% FCS. Samples were analyzed using a FACSCalibur (Becton Dickinson, Heidelberg, Germany).
Immunohistology. Cryostat sections (5 Am) of snap-frozen tissue were fixed in chloroform/acetone (1:1) for 4 minutes. Tissues were incubated for 1 hour with the first antibody, washed, and exposed to the biotinylated secondary antibodies (30 minutes) and alkaline phosphatase -conjugated avidin-biotin complex (Vector Laboratories, Grü nberg, Germany) solutions (5-20 minutes). Tissue sections were counterstained with Mayer's hematoxylin. The primary antibody was replaced with normal mouse, rat, or rabbit IgG for negative controls.
For immunofluorescence microscopy, cells were seeded on laminin 5-coated cover slides. (w/v in PBS) and, where indicated, were permeabilized (4 minutes, 0.1% Triton X-100). After washing and blocking (0.2% gelatin, 0.5% bovine serum albumin in PBS), cells were incubated with the primary antibody (2-10 Ag/mL) in PBS/bovine serum albumin for 60 minutes at 4jC. Slides were rinsed and subsequently incubated for 60 minutes at 4jC with a fluorochrome-conjugated secondary antibody. After washing, free binding sites were blocked by incubation with an excess of unlabeled mouse or rat IgG. Unlabeled mouse or rat IgG was also added during incubation with the second, directly labeled antibody (60 minutes, 4jC). For cross-linking, cells were incubated at 37jC for 15 minutes with the primary antibody and for 20 minutes with an excess (10 Ag/mL) of the secondary, dye-labeled antibody. Cells were washed with ice-cold PBS and all consecutive steps were done at 4jC. After washing, slides were mounted in Elvanol. Digitized images were generated using a Leica DMRBE microscope equipped with a SPOT CCD camera from Diagnostic Instruments, Inc. and Software SPOT2.1.2.
Substrate. Laminin 5 was a kind gift from K. Miyazaki (Division of Cell Biology, Yokahama City University, Yokohama, Japan; ref. 35) . Plates were coated with 0.3 Ag/mL laminin 5 and free binding sites were blocked by incubation with PBS/1% bovine serum albumin.
Immunoprecipitation. Cells (1 Â 10 7 ) were lysed (4 hours, 4jC) in 4 mL ice-cold lysis buffer [25 mmol/L HEPES, 150 mmol/L NaCl, 5 mmol/L MgCl 2 (pH 7.2)] containing 1% Brij58 or 1% Brij96. Lysis buffers contained a protease inhibitor cocktail (Boehringer Mannheim, Mannheim, Germany) and 2 mmol/L phenylmethylsulfonyl fluoride. After centrifugation for 30 minutes at 15,000 rpm, lysates (1 mL) were precleared by incubation with 1/10 volume protein G Sepharose and protease inhibitor cocktail (2 hours, 4jC). Precleared lysates were incubated overnight at 4jC with 1 Ag of antibody or control IgG. Protein G Sepharose was added for an additional 2 hours. Immune complexes were washed four to six times with lysis buffer and precipitated proteins were eluted with 50 AL of 100 mmol/L glycine (pH 2.7). Immunoprecipitated proteins were analyzed by SDS-PAGE, followed by Western blotting.
Western blotting. Lysates and immunoprecipitated proteins were resolved on 12% or 15% SDS-PAGE under nonreducing conditions and the proteins were transferred to Hybond enhanced chemiluminescence at 30 V overnight. After blocking (5% fat-free milk powder), immunoblotting was done with the indicated antibodies, followed by rabbit antimouse horseradish peroxidase. Blots were developed with the enhanced chemiluminescence detection system. Densitometric analysis was done with NIH Image 1.60 software.
Adhesion and migration. In adhesion assays, cells were incubated with [ 3 H]thymidine for 16 hours, washed, and seeded in triplicate on laminin 5-coated flat-bottomed 96-well plates. After incubation (120 minutes, 37jC) and vigorous washing, remaining adherent cells were detached with 0.2% trypsin. Cells were harvested and counted in a hcounter. Where indicated, 10 Ag/mL antibodies were added during incubation.
Cell migration was evaluated using a scratch assay or a modification thereof, where Petri dishes were coated with laminin 5 as described above. Thereafter, the central area of the Petri dishes was covered with a cover slide (6 mm diameter). When tumor cells seeded on laminin 5-coated Petri dishes reached near-confluence, the cover slide was removed, medium was aspirated, plates were washed, and RPMI supplemented with 1% FCS and, where indicated, 10 À8 mol/L PMA was added. Mean values and SDs of the number of cells migrating in the originally cell-free area were evaluated by counting 10 fields of 1 mm 2 at the boundary towards the originally cell-free area using an inverted microscope at 24 and 48 hours after removal of the cover slide. Values represent the mean of three independently performed experiments. Alternatively, subconfluent monolayers were scratched with a blunt-edged needle. Plates were incubated for 48 hours, washed, fixed, and stained with H&E.
Statistics. Significance of differences was calculated by the twotailed Student's t test or the two-sided Wilcoxon exact test with P values adjusted according to Bonferroni-Holm.
Results
Clinical studies provide evidence for a significant acceleration of metastasis of pancreatic tumors after isolated tumor cells have settled in the peritoneal cavity (36) . Furthermore, the association of integrins with tetraspanins has been suggested to promote cell motility (27 -29, 37 express defined integrin and tetraspanin patterns, whether and which integrins associate with tetraspanins, and whether the association is accompanied by altered cell motility.
Integrin and tetraspanin expression. Expression of a1 to a6, aL, h1, h2, and h4 and of CD9, CD53, CD63, CD81, CD82, CD151, and CO-029 was evaluated by flow cytometry in 10 pancreatic adenocarcinoma and 9 colorectal cancer lines (Table 1 ). All tumor lines expressed a2, a3, a6 and h1, and 18 of 19 tumor lines expressed h4. h4 expression mostly exceeded that of h1. Weak a1 and a4 expression was only rarely observed. The tumor lines did not express aL, h2, or CD53. CD63, CD81, and CD82 were expressed by all tumor lines. CD151 was expressed to some extent on all cell lines, and strongly on 70% of pancreatic adenocarcinoma and 89% of colorectal cancer lines. With the exception of two colorectal cancer lines, cells expressed CD9. CO-029 was moderately expressed in 79% of colorectal cancer and 40% of pancreatic adenocarcinoma lines.
To exclude an in vitro artifact due to long-term culture, integrin and tetraspanin expression was evaluated on primary tumor tissue sections ( Table 2 ). The expression profile on tissue samples did not differ significantly from that of tumor lines. Over 90% and 80% of pancreatic adenocarcinoma tissue moderately expressed a6 and h4, respectively. CD9, CD63, CD81, and CD151 were expressed by nearly all pancreatic adenocarcinoma tissues. CO-029 expression was higher in pancreatic adenocarcinoma tissues (>80%) than in lines. a1, a3, a6, h1, and h4 were also expressed by normal pancreatic tissue, albeit at a low level, and by chronic pancreatitis tissues, where a3, a6, h1, and h4 expression was distinctly upregulated. Normal pancreatic tissue expressed CD9, CD63, CD81. Ductal cells expressed moderately CD151 and CO-029 and, at a very low level, CD82. Expression of CD151 and CO-029 on ductal cells was up-regulated in chronic pancreatitis as compared with normal pancreatic tissue.
When tumor tissues were grouped according to grading and staging, statistical analysis provided some significant differences despite the great variability between different tumors. No significant differences were seen between papillary and ductal pancreatic adenocarcinoma. There were no grade 1 pancreatic adenocarcinomas. Grade 3 pancreatic adenocarcinoma expressed h1 and CD9 at a higher level, and CD151 at a lower level than grade 2 tumors, the difference in CD9 expression 
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on January 13, 2018. © 2005 American Association for clincancerres.aacrjournals.org Downloaded from being highly significant. Highly significant differences (P < 0.01) were also seen in h1 and CD9 expression of pancreatic adenocarcinoma tissues from patients with liver metastasis. CD9, h1, and a3 expression was also high in the two metastatic tissues, which hardly expressed CD82. However, the low number of metastatic tissues prohibited a statistical evaluation (Table 3) .
The high expression of CD9 and (a3)h1 in grade 3 and advanced tumors was unexpected, since both markers have been associated with good prognosis (5, 6, 18 -21) . However, pancreatic adenocarcinomas are characterized by the induction of a strong stromal reaction and tumor surrounding fibroblasts differed from fibroblasts in normal pancreatic tissue in as much as they frequently and strongly expressed CD9 and CD151 (Fig. 1A) . (Fig. 1B) confirmed that CD9 and CD63 were preferentially expressed on stromal cells, whereas h4 was preferentially expressed by tumor cells, i.e., in the PaCa122 line, which contains few tumor cells, h4 was minimally expressed by CD9+ cells, whereas the majority of h4-expressing cells were CD151+ and CO-029+. CD151 was expressed by tumor cells and stromal cells and CO-029 was expressed predominantly by tumor cells. The result was not as clear-cut for CD81 and CD82, inasmuch as some, but not all, CD81+ and CD82+ cells were h4+. Nonetheless, the analysis of these tumor/stroma cell lines confirmed that h4 and CO-029 are expressed predominantly by tumor cells, whereas CD9 and CD63 are expressed more strongly by tumor-associated fibroblasts than the tumor cells.
Taken together, tumor lines and tissues mostly express a3 and h1 at an intermediate, and a6 and h4 at a high level, although not all tumors express h4. Expression of CD9, CD63, CD81, CD82, CD151, and CO-029 is frequently high. CD9 and CD63 are also strongly expressed on the tumor stroma. CD82 is rather tumor-specific, but is not expressed by all tumors.
Colocalization and association of integrins and tetraspanins. Tetraspanins frequently associate with integrins (38) Tumor line CD9 CD81 CD151 CD9 CD81 CD151 CD9 CD81 CD151 CO-029 CD9 CD81 CD151 CO-029
Pancreatic cancer A s P C 1 + + n t + + n t
Abbreviations: nt, not tested; na, not applicable (cell lines with no, very weak, or weak expression were excluded).
*Degree of colocalization: J, very weak; F, weak; +, distinct; ++, strong.
a6b4 and Tetraspanins in Pancreatic Cancer
Cancer Research. , 37jC ) and the secondary, rhodamine-labeled antibody (30 minutes, 37jC). Cover slides were placed on ice, washed, blocked, and stained with the second, FITC-labeled antibody (1hour, 4jC). After washing, cells were embedded in Elvanol. Digitized images were generated. Single stainings and merged overlays are shown. Colocalization is indicated by yellow staining; bar, 50 Am. B, 8.18 cells were lysed in Brij96 and lysates were precipitated with anti-a3 or anti-h4 or anti-transferrin receptor as control. After SDS-PAGE and transfer, membranes were blotted with anti-CD151, anti-CO-029, and anti-CD9. CD151was detected in a3 and h4 precipitates and CO-029 in a3 precipitates. CD9 was not detected in either a3 or in h4 precipitates; the latter also did not contain CO-029. C, 8.18, Capan1, SW707, and WIDR cells were lysed in Brij58. Lysates were precipitated with anti-a3 and anti-h4. After SDS-PAGE and transfer, membranes were blotted with anti-CD9 and anti-CO-029. a3 precipitates contained CD9 and CO-029, h4 precipitates contained only CO-029. From 10 tested lines (only 4 lines are shown), only the SW707 line differed in as much as anti-h4 precipitated CD9, but not CO-029, whereas a3 precipitates contained CD9 and CO-029. All experiments were repeated at least thrice. A representative example is shown.
Human Cancer Biology
Cancer Research. it was important to determine whether and which integrins would colocalize and/or associate with tetraspanins. Colocalization was evaluated by fluorescence microscopy ( Table 5 , Fig. 2A ). In most pancreatic adenocarcinoma and colorectal cancer lines, a3 and h1 distinctly colocalized with CD9 (12 of 20) and CD81 (14 and 16 of 20). Colocalization of a3 and h1 with CD151 (evaluated for 7 lines) was seen in all instances. The a6 integrin colocalized distinctly with CD9 in only 8 of 20 and with CD81 in 7 of 22 tumor lines. Colocalization of h4 with CD9 (5 of 19) and CD81 (4 of 21) was rare, indicating that CD9 and CD81 preferentially colocalized with a3h1 rather than a6h1 integrins. Colocalization of a6 with CD151 and CO-029 (11 of 22 and 7 of 18) mostly coincided with colocalization of h4 with CD151 (11 of 21) and CO-029 (9 of 18). The latter colocalization was also seen in the freshly explanted P106 and P122 cells. Thus, a3h1 frequently colocalized with CD9, CD81, and CD151. In contrast, a6h4 colocalized mostly with CD151 and CO-029.
To see whether colocalization corresponds to protein association, coimmunoprecipitation of a3(h1) and (a6) h4 with CD9, CD151, and CO-029 was evaluated ( Fig. 2B and C ). CD151 coimmunoprecipitated with a3 and h4 after stringent lysis in Brij96. a3 precipitates, but not h4 precipitates, contained CO-029. CD9 was not detected in a3 or h4 precipitates after Brij96 lysis. In contrast, after mild lysis in Brij58, a3 precipitates from all tested lines contained CD9 and, with the exception of the SW707 line, CO-029. Also with the exception of the SW707 line, h4 coprecipitated CO-029, but not CD9 (Table 6) .
Thus, coimmunoprecipitation confirmed the associations of CD151 and CD9 with a3h1 (28, 39) and of CD151 with a6h4 (31). CO-029 associates with a3h1 and under mild lysis conditions with a6h4. Notably, with the exception of one colorectal cancer line, a6h4 did not associate with CD9. High a3h1 (5, 6) and CD9 (18 -21) expression are frequently associated with a good prognosis, whereas high a6h4 (9), CD151, and CO-029 (18, 24) expression indicate a poor prognosis. Taking into account that a6h4 associated only with CD151 and CO-029, we speculated that this association may have an impact on tumor cell motility.
The impact of integrin-tetraspanin complexes on tumor cell migration. The a3h1 and a6h4 integrins both bind to laminin 5 (40) and all tested lines bound more strongly to laminin 5 than to bovine serum albumin. Laminin 5 binding was reduced in most lines in the presence of blocking anti-a3 and anti-h4. Panc89 and Colo357 were exceptions in that laminin 5 binding of Colo357 cells was not inhibited by anti-a3 and Panc89 binding was not inhibited by anti-a3 and h4. PKC activation can support cell migration by inducing internalization of tetraspanin-integrin complexes (41) . In fact, laminin 5 adhesion was strongly reduced in AsPC1, Capan1, and HT29 cells, distinctly in Colo357 and 8.18 cells and weakly in WIDR cells after PMA treatment (Fig. 3A) . Furthermore, reduced laminin 5 adhesion after PKC activation correlated mostly with increased cell motility (Fig. 3B) . Migration of cells out of a semiconfluent monolayer into a cell-free area, which had been protected by a cover slide, was evaluated after 24 hours. Whereas the number of migrating Panc89 and WIDR cells was independent of the presence of PMA, AsPC1, Capan1, Colo357, 8.18, and HT29 cells migrated more readily. The finding was confirmed when a monolayer was stained 48 hours after wounding with a blunt-edged needle (Fig. 3C) . Wound closure of AsPC1, Capan1, Colo357, 8.18, and HT29 cells was more advanced in the presence than in the absence of PMA. Thus, PKC activation was accompanied by reduced laminin 5 adhesion in those lines that gained in motility. The two lines where PMA treatment had no impact migrated very rapidly even without PKC activation.
As increased migration after PMA treatment correlated with reduced laminin 5 adhesion, we speculated that PMA treatment might be accompanied by redistribution and/or changes in integrin-tetraspanin colocalization. We hypothesized that the association of a6h4 with CD151 and CO-029, rather than the association of a3h1 with CD9, might account for increased tumor cell motility. Therefore, we compared the impact of PMA treatment on the a3h1-CD9, a6h4-CD151, and a6h4-CO-029 association.
Cells were seeded on laminin 5-coated plates and treated for 1 or 2 hours with PMA. In most lines, a6h4 colocalized more readily with CD151 and CO-029 after PMA treatment ( Table 7) . Quantification of coimmunoprecipitates revealed that anti-a3 precipitated less CD9, CO-029, and CD151, whereas anti-h4 precipitated increased amounts of CO-029 and CD151 (Table 8) . a6h4-CD151 and a6h4-CO-029 complexes had disappeared from the cell membrane after 1 hour of PMAtreatment and became enriched in the perinuclear region. After 2 hours of PMA-treatment, the codistribution of a6h4-CD151 and a6h4-CO-029 differed in the individual lines. In Capan1 cells, whose motility was strongly influenced by PMA treatment, a6h4-CD151 and a6h4-CO-029 complexes remained diffusely dispersed and were not enriched at the membrane. In HT29, whose migratory activity was less increased, and in WIDR cells, which moved independently of PMA treatment, the complexes were enriched or exclusively located at the cell membrane. In WIDR cells, CO-029 and h4 colocalized at the migratory front of the leading lamella ( Fig.  4B and C) . After 4 hours of PMA treatment, CO-029 and CD151 colocalized with h4 in the leading lamella of all three lines (data not shown). We did not observe a similar coincidence of increased motility, increased colocalization and internalization for a3 and CD9 in PMA-treated tumor cells. Without PMA treatment, a3h1-CD9 colocalization was most pronounced at cell-cell contact sites, where a6h4-CD151 and a6h4-CO-029 rarely colocalized. This can best be seen with WIDR cells, which tend to grow in clusters. After PMAtreatment, a3-CD9 colocalization was mostly seen in the cytoplasm of all lines (Fig. 4A) .
Thus, PKC activation supported the association of a6h4 with CD151 and CO-029. a6h4-CD151/CO-029 complexes were transiently enriched in the cytosol, mostly in the perinuclear region, but reappeared-with a cell line-dependent kinetic-at the leading lamella. A3h1-CD9 colocalization was most pronounced at cell-cell contact sites. Upon PMA treatment, cell-cell contacts became loose, a3h1-CD9 complexes became diffusely distributed in the cytoplasm and, in contrast to a6h4-CD151/CO-029, less a3h1 associated with tetraspanins. Thus, only the a6h4-CD151/CO-029 associations were strengthened by PKC activation and increased colocalization correlated with increased cell motility.
Discussion
Pancreatic adenocarcinomas have a poor prognosis due to early and massive spread into the peritoneal cavity and settlement in the liver (1, 3, 4) . Several reports indicate a contribution of a3h1 and a6h4 (5, 42) . We noted in a highly metastatic rat pancreatic adenocarcinoma line that a6h4 associated with CO-029 after PKC activation. was determined in a h-counter. The percentage of adherent cells (mean F SD of triplicates) is shown; *, significant differences (P < 0.01). B, tumor cells were seeded on laminin 5-coated Petri dishes, where the central area had been covered by a cover slide. When cells reached subconfluency, the cover slide was removed and medium was exchanged. Where indicated, the added medium containing 10 À8 mol/L PMA. Cells, which had moved into the area protected by the cover slide, were counted after 24
hours. Columns, mean; bars, F SD of three plates; *, significant differences (P < 0.01). C,Tumor cells were seeded on laminin 5-coated Petri dishes. When cells reached subconfluency, the monolayer was wounded with a blunt tweezer and medium was exchanged as in (B). Cells were cultured for an additional 48 hours in the presence or absence of 10 À8 mol/L PMA. Petri dishes were washed and stained with H&E. Migration into the wounded area in the presence or absence of PMA is shown; bar, 50 Am. Experiments were repeated at least thrice.
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Cancer Research. (34) . In view of these observations, we speculated that coexpression of integrins, particularly of a6h4, and tetraspanins, may be a key element in the metastatic behavior of pancreatic adenocarcinoma. Here, we show high expression of several integrins and tetraspanins in pancreatic adenocarcinoma tissues and lines in comparison to normal pancreatic and chronic pancreatitis tissues. Furthermore, laminin 5-binding integrins were found in association with tetraspanins. However, only the a6h4-CD151/CO-029 associations were strengthened by PKC activation, which was frequently accompanied by increased motility. We suggest that a6h4-CD151/CO-029 complexes might promote the massive metastatic spread of pancreatic adenocarcinoma.
Integrin and tetraspanin expression in tumors and tumor stroma. A recent study on molecular profiling of pancreatic adenocarcinoma defined a2, a3, and h4 significantly upregulated in comparison to normal and chronic pancreatitis tissue (13) . This is well in line with our findings, which show, in addition, strongly up-regulated a6 and h1 expression in chronic pancreatitis. However, expression remained restricted to the basal membrane, whereas the orientation was lost in pancreatic adenocarcinoma. Furthermore, in freshly explanted pancreatic adenocarcinoma tissue, where islets of tumor cells could be clearly distinguished morphologically from the tumor stroma, a1, a2 and a3 were expressed at a high level. As those integrins are weakly expressed in normal pancreatic tissue, it is likely that their high expression on the tumor stroma may contribute to tumor cell survival. The strong stromal reaction of many pancreatic adenocarcinomas may also account for the reported differences in integrin expression of pancreatic adenocarcinoma (6, 43) . Taken together, pancreatic adenocarcinoma and colorectal cancer do not differ significantly, but differ from healthy and inflamed tissue by a1, a2, a3, and h4 overexpression. Tumor stroma is characterized by a1, a2, a3, and h1 up-regulation.
In relation to the impact of tetraspanins on pancreatic adenocarcinoma progression, CD82 and CD9 mRNA levels have been reported to correlate inversely with histopathologic grading and survival time, whereas CD63 mRNA levels appeared to be independent of grading and staging (20) . We also noted that tetraspanin expression varies between healthy, chronically inflamed, and cancerous tissue. CD63 expression was slightly increased in chronic pancreatitis and pancreatic adenocarcinoma as compared with healthy tissue. As reported (44) Table 7 . Protein kinase C activation and colocalization (19 -21) . CD81 expression was distinctly increased in pancreatic adenocarcinoma. CD151 was weakly expressed in healthy tissue, moderately in chronic pancreatitis, and strongly in most pancreatic adenocarcinoma. CO-029 was moderately expressed on ductal cells, expression was up-regulated in chronic pancreatitis and was strong in pancreatic adenocarcinoma, although not in all tumors. Tumor stroma did not express CO-029. CD82 was the only tetraspanin not expressed by normal pancreatic tissue and very weakly by chronic pancreatitis tissue, but strongly by nearly 50% of pancreatic adenocarcinoma. Thus, CD82 can be considered as a distinct tumor marker. The finding was unexpected, because CD82 has been described repeatedly to inhibit metastasis formation (19, 21, 23, 43, 45) and pancreatic adenocarcinoma are highly metastatic. Correlating CD82 expression with tumor grading and disease state, indeed, revealed very low CD82 expression on local recurrences and liver metastases. However, the number of recurrent/metastatic tissues was too low for a statistical evaluation. Thus, further studies are required to unravel whether this metastasis-inhibitory molecule becomes down-regulated only at a late stage of pancreatic adenocarcinoma progression, which actually has been observed in prostate cancer (46) .
Integrin-tetraspanin colocalization in pancreatic and colorectal cancer. Tetraspanins form multimolecular complexes that frequently include integrins (25 -28) . The tetraspanin CD151 strongly associates with a3h1 (28, 47) and a6h4 (31) . CD9 associates preferentially with a3h1 and a6h1 (39, 48) . CD81 forms complexes with a3h1, a4h1, and other integrins (39, 49) . We described an association of the rat CO-029 homologue with a6h1, a3h1 (14) and, outside of hemidesmosomes, with a6h4 (34). This colocalization pattern largely resembles that of CD151 with laminin-binding integrins (31) . Our findings on pancreatic adenocarcinoma and colorectal cancer are in line with the described features and confirm that the a6h4-CD151, . Colocalization and redistribution of a3-CD9 and h4-CD151/CO-029 after PKC stimulation. Capan1, HT29, and WIDR cells were seeded on cover slides, starved, and cultured for 1or 2 hours in the presence of 10 À8 mol/L PMA. Cells were fixed, permeabilized, and stained with the first antibody and a rhodamine-labeled secondary antibody. After washing and blocking, cells were stained with the second, FITC-labeled antibody. Digitized images were generated. Single stainings and merged overlays are shown for (A) a3 and CD9, (B) h4 and CD151, (C) h4 and CO-029; bar, 10 Am.
Cancer Research. but not the a6h4 and CO-029 complex resists lysis in detergents of intermediate strength (31) . As tetraspanins can mutually associate (50), we hypothesize that CO-029 associates rather with CD151 than with the integrin. Several observations support the hypothesis: the coimmunoprecipitation pattern of CO-029 with a3h1, a6h1, and a6h4 overlaps with the coimmunoprecipitation pattern of CD151 (31) ; colocalization of a3h1 with CD9 was most strong at cell-cell contact sites (37) , where a6h4-CD151/CO-029 colocalization was less prominent; PMA treatment strengthened the a6h4-CD151/ CO-029, but weakened the CD9-a3h1 association; PMAinduced internalization of CD151, CO-029, and h4 was similar, but was different from that of CD9 and a3.
a3h1-CD151 complexes resist strong detergents and are observed at a high stoichiometry (50) . Our findings of a preferential association of CD151 with a6h4 could well be explained by the studies of Sterk et al. (31) , which showed efficient competition of a6h4 for CD151 within hemidesmosomes such that a3h1 was dislodged towards focal adhesion sites and only part of CD151 remained associated with a3h1. Sterk et al. (31) also described exclusion of CD9 from CD151-a6h4 complexes and we noted that this also accounts for CD151-CO-029-a6h4 complexes with the exception of SW707 cells. Thus, we would argue that in the absence of a6h4 or laminin 5, a3h1 is found in clusters with CD151, CD9, and CO-029. In contrast, in CD151-a6h4 clusters, CO-029 remains preferentially associated with a6h4 via CD151, whereas CD9 remains associated with a3h1. The reason for this supposed ''reorganization'' of tetraspanin-integrin complexes remains to be explored. It could be due to a competition of the integrins for laminin 5 or to differences in the cytoplasmic regions of the tetraspanins. Thus, CO-029 and CD151, but not CD9, have a tyrosine-based internalization motif (38) , which could account for CO-029-CD151-a6h4 complex guidance into recycling vesicles.
The impact of tetraspanin-integrin complexes on tumor cell motility. Tetraspanin-integrin complexes contribute to cellcell adhesion (19, 27, 37, 38) , relocation of tetraspanin complexes to actin-based structures (51) and are proposed to account for turnover and sorting of associated integrins (19, 27, 37, 38) . Because we observed (a) that a3h1 preferentially colocalized with CD9 at cell-cell contact sites, where colocalization of CD151 and CO-029 with a6h4 was hardly detected; and (b) that re-expression after PMA-induced internalization of CD151-CO-029-a6h4 differed from that of a3h1-CD9 complexes, we wondered whether these tetraspanin-integrin complexes might have a different impact on tumor cell motility.
In fact, tumor lines which displayed reduced adhesion in the presence of anti-h4, were also poorly adhesive after PMA treatment and showed improved migration. In contrast, anti-h4 did not affect the adhesiveness of Panc89 cells, which did not increase migration after PMA treatment. Furthermore, the PMAinduced increase in colocalization of CD151-CO-029-a6h4 as well as the strength of internalization correlated with increased motility and decreased adhesiveness. Finally, AsPC1, Capan1, Colo357, 8.18, and HT29 cells, which gained in motility as a result of PKC activation, have been described as (highly) metastatic, whereas WIDR and Panc89 are defined as low or nonmetastatic (see supplement, Table S2 ). Thus, stimulationinduced internalization of CD151/CO-029 and a6h4 may enhance tumor cell motility and contribute to the high metastatic potential of pancreatic adenocarcinoma and colorectal cancer after dissemination in the peritoneal cavity, which can provide a stimulatory milieu.
Expression of several integrins and tetraspanins is upregulated in pancreatic adenocarcinoma and colorectal cancer, and a3h1 as well as a6h4 form complexes with CD9, CD151 and/or CO-029. However, only the a6h4-CD151/CO-029 association seems to contribute to cell motility. In metastasizing pancreatic and colorectal carcinoma lines, PKC activation is accompanied by transient internalization of a6h4-CD151/CO-029 complexes, changes in cell shape towards a migratory phenotype and increased motility. The formation of this integrin-tetraspanin complexes could well be a key feature for the high motility of pancreatic adenocarcinoma and colorectal cancer cells and their pronounced metastatic progression after settling in the peritoneal cavity. 
